A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

Within this global landscape, the EXO 001 targeted exosome platform--developed jointly by CMUH and Ever Supreme Bio Technology--stands out for its use of high-biocompatibility, naturally derived ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

For San Diego researchers and the wider immunotherapy community, the atlas functions as a practical roadmap. It does not ...

The BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine has gone in this eighteenth edition to Carl June ...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company has initiated enrollment in what it described as its first pivotal program ...

Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T ...

EB103 utilizes Eureka’s ARTEMIS technology, a platform designed to harness the human immune system more effectively than standard therapies. The ARTEMIS T cells are engineered to address the specific ...

Chairman and CEO Dr. Amit Kumar said the company views 2026 as a “pivotal year” as it advances two clinical-stage programs: a ...